David J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, Alexandra Emilia Schlaak, Ciro Celsa, Saskia Killmer, Jesus Miguens Blanco, Caroline Ward, Charalampos-Vlasios Stikas, Mark R Openshaw, Nicole Acuti, Georgios Nteliopoulos, Cristina Balcells, Hector C Keun, Robert D Goldin, Paul J Ross, Alessio Cortellini, Robert Thomas, Anna Mary Young, Nathan Danckert, Paul Tait, Julian R Marchesi, Bertram Bengsch, Rohini Sharma
BACKGROUND: TACE may prime adaptive immunity and enhance immunotherapy efficacy. PETAL evaluated safety, preliminary activity of TACE plus pembrolizumab and explored mechanisms of efficacy. METHODS: Patients with liver-confined HCC were planned to receive up to 2 rounds of TACE followed by pembrolizumab 200 mg every 21 days commencing 30-days post-TACE until disease progression or unacceptable toxicity for up to 1 year. Primary endpoint was safety, 21-days dose-limiting toxicities (DLT) from pembrolizumab initiation...
April 5, 2024: Clinical Cancer Research